Health Care·Pharmaceuticals·$547.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.36 | N/A | +3.42% |
management commentary, guidance changes, and full analysis available with Pro.
| +3.42% |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting a commitment to operational improvements. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on improving operational efficiency.
This earnings report shows that Johnson & Johnson managed to exceed EPS expectations, indicating solid performance in this area. However, the lack of revenue data and guidance leaves some uncertainty about future growth. The stock reaction was not available, making it difficult to gauge investor sentiment immediately following the report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
INTEL CORP
Oct 15, 2013